BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Cancer drug pollution is a growing global concern 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
McDonald's China Faces Backlash for Food Hygiene Violations 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
NEWARK, Calif., Feb. 02, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet need, today announced the pricing of its previously announced underwritten public offering of 5,181,348 shares of its common stock at a public offering price of $1.93 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by CymaBay. In addition, CymaBay has granted the underwriters a 30-day option to purchase up to an additional 777,202 shares of common stock at the public offering price less underwriting discounts and commissions solely to cover over-allotments, if any. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.
The offering is expected to close on February 7, 2017, subject to the satisfaction of customary closing conditions.
JonesTrading Institutional Services LLC is acting as the sole book-running manager for the offering, and LifeSci Capital LLC is acting as the lead manager.
The securities described above are being offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website at: http://www.sec.gov/. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from JonesTrading Institutional Services LLC, 757 3rd Avenue 23rd Floor NYC, NY 10017 or by calling JonesTrading Institutional Services LLC toll-free at (800) 423 -5933; or LifeSci Capital LLC at 250 West 55th Street, Suite 16B, New York, NY 10019, or by calling (646) 597-6987, or by emailing [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. CymaBay has recently completed a Phase 2 study of seladelpar in patients with primary biliary cholangitis as well as a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications.
Cautionary Statements
This announcement contains forward-looking statements, including statements relating to CymaBay’s expectations regarding the completion of the proposed public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. CymaBay cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. There can be no assurance that CymaBay will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to CymaBay and its business can be found in the “Risk Factors” section of CymaBay’s Form 10-K for the year ended December 31, 2015, filed with the SEC on March 29, 2016, and Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016, and in the preliminary prospectus supplement contained in the registration statement related to the proposed offering filed with the SEC on February 1, 2017, and the prospectus supplement contained in the registration statement related to the proposed offering to be filed with the SEC. CymaBay undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in CymaBay’s expectations.
Contacts: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] or Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
